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Pharmacovigilance (PV) department plays an
important and critical role in the drug development
progress. According to WHO, PV, also known as drug
safety, is the pharmacological science relating to the
collection, detection, assessment, monitoring, and
prevention of adverse effects with pharmaceutical
products. The safety of pharmaceutical product
may not be well defined. When drugs are used in
combination, its’ post effects are generally unknown
and safety concerned in different groups can be
different as in young children, elderly patients and
pregnant women.
Pharmacovigilance was introduced in Research
and academic world with the establishment of the
International Society of Pharmacoepidemiology
(ISPE) in the year 1984 and of The European
Society of Pharmacovigilance (ESOP – later ISOP –
the International Society) in 1992, which further led
to its incorporation into clinical practice. (1)
1. Objectives of pharmacovigilance
• To detect the risk factors associated with
drugs
• To identify unknown safety problems
• To quantify the probability of risk
• To measure the effectiveness(1)
2. The national pharmacovigilance centres
At present, post-marketing surveillance of
medicines is mainly co-ordinated by national
pharmacovigilance centres. The collaboration
of National centres with the UMC (the Uppsala
Monitoring Centre-The WHO Collaborating
Centre for International Drug Monitoring) have
achieved a great deal in:
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• collecting and analysing case reports of
ADRs
• distinguishing signals from background
‘noise’
• making regulatory decisions based on
strengthened signals
• alerting prescribers, manufacturers and the
public about new risks of adverse reactions
Further, the extent of activities of the National
centres has expanded including notification of
information about benefit, harm, effectiveness and
risk to practitioners, patients and the public. Major
centres in developed countries have established
active surveillance programmes using record
linkage and prescription event monitoring systems
(PEM) to collect epidemiological information on
adverse reactions to specific drugs. Such systems
have already been implemented in New Zealand, the
United Kingdom, Sweden and the United States of
America.
As the drug information is rapidly increasing
across the world, the need for routine and rapid
communication between National Centres and
national regulatory authorities has also increased.
Many regulatory authorities in different regions
of the world have developed close ties with each
other to discuss safety data obtained on particular
medicines and the regulatory decisions being
made in response to them.(2,3) (The importance of
pharmacovigilance, safety monitoring of medicinal
products, WHO 2002, Page 11)
2.1 Pharmacovigilance in different countries/
regions
Based on the WHO guidelines, all the regions
of the world have their own particular
Pharmacovigilance system.

How to cite this article: Sagar P. Awareness of Pharmacovigilance. MJPS 2016; 2(2): 1-3.

Manipal Journal of Pharmaceutical Sciences | September 2016 | Volume 2 | Issue 2

Published by Impressions@MAHE, 2022

1

1

Manipal Journal of Pharmaceutical Sciences, Vol. 2 [2022], Iss. 2, Art. 1
Sagar P: Awareness of Pharmacovigilance

2.1.1 Pharmacovigilance in Europe
In Europe, the Pharmacovigilance system is
called EUDRA vigilance, which has separate
but similar database for human and veterinary
adverse reactions. This system is coordinated
by European Medicines Agency (EMA)
and conducted by the National Competent
Authorities (NCAs). The EMA maintains
and develops the Pharmacovigilance database
comprising all suspected serious adverse drug
reaction observed in the European region. EMA
Pharmacovigilance legislation regulated by
Article 106 of Directive 2001/83/EC, Directive
2001/20/EC & Article 26 of Regulation (EC)
No. 726/2004 EMEA& EC.(4)
2.1.2 Pharmacovigilance in United States
Here Pharmacovigilance has a multiple approach.
Three branches of Pharmacovigilance in the
USA have been defined by the FDA to evaluate
product risks and promote the safe use of
products by the American people. These three
divisions / branches come under the Office of
Surveillance and Epidemiology (OSE).(4)
Three Divisions within OSE:
1. Division of Drug Risk Evaluation (DDRE)
2. Division of Medication Errors and Technical
Support (DMETS)
3. Division of Surveillance, Research and
Communication Support (DSRCS)
2.1.3 Pharmacovigilance in India
Based on the WHO recommendations made
in the document titled, “Safety monitoring of
Medicinal products-guidelines for setting up
and Running a Pharmacovigilance Centre”, the
Central Drugs Standard Control Organisation
(CDSCO), ministry of health and family
welfare, Govt of India launched the National
Pharmacovigilance
Program
(NPP)
in
(4)
November, 2004.
3. Pharmacovigilance in drug regulation
Drug regulatory systems provide the basis for, a
national philosophy of drug safety and increasing
the confidence of public in medicines. The drug
regulatory authorities have to deal with many
issues for the approval of new medicines, which
includes
2

•
•

clinical trials
safety of complementary and traditional
medicines, vaccines and biological medicines
• developing lines of communication between all
parties with an interest in drug safety and
ensuring that they are open and able to function
efficiently, particularly at times of crisis.
There is need of strong linkage between PV
programs and drug regulators to assure that
the authorities are well concise on safety issues
in everyday practice, which can have an impact
on future regulatory action. Regulators are
well acquainted with a unique and pivotal role
of PV in ensuring ongoing safety of medicinal
products. Hence, for the achievement of the PV
objectives, there is need of adequate support for
PV programmes.
For the approval of a new drug by the national
drug regulatory authority, it must pass through
three obstacles
Sufficient evidence is required to show the new
drug to be
• of good quality,
• effective, and
• safe for the purpose or purposes for which it
is proposed.
Whereas the first two criteria must be met before
any consideration can be given to approval,
the issue of safety is less certain. Safety is not
absolute, and it can be judged only in relation to
efficacy, requiring judgment on the part of the
regulators in deciding on acceptable limits of
safety. [2, 3]
3.1 Post-marketing safety monitoring
To avoid loss of important innovations in an
extremely restrictive regulatory network, the
process of evaluating drug safety needs to
happen in the post-marketing (approval) phase.
Judgment as to whether and how to evaluate
data lies with the regulators.
The early release of new drugs with their
therapeutic advances depends on the
pharmacovigilance and ADR reporting,

Manipal Journal of Pharmaceutical Sciences | September 2016 | Volume 2 | Issue 2

https://impressions.manipal.edu/mjps/vol2/iss2/1

2

Sagar: Awareness of Pharmacovigilance
Sagar P: Awareness of Pharmacovigilance

the stronger the national system of
pharmacovigilance and ADR reporting, there
will be early release of new drugs. Legislation
governing the regulatory process in most
countries allows for conditions to be placed
on approvals, such as a requirement that there
should be detailed pharmacovigilance in the
early years after a drug’s release.
There are other aspects of drug safety that have
been rather neglected until now but should be
included in monitoring latent and long-term
effects of medicines. These include:
• detection of drug interactions
• measurement of the environmental burden
of medicines used in large populations
• assessment of the contribution of ‘inactive’
ingredients (excipients) to the safety profile
• systems for comparing safety profiles of
similar medicines
• surveillance of the adverse effects on human
health of drug residues in animals, e.g.
antibiotics and hormones.
drug
3.2 -International harmonization of
regulatory requirements
In the last few decades, multinational
organizations at regional and inter-regional
levels harmonized the various elements of drug
regulatory activities, which are being followed in
all WHO regions. The increase of global trade
in pharmaceutical products and the growth in
complexity of technical regulations related to
drug safety and quality leads to these efforts.
The ICH initiative, which started in 1990, is an
inter-regional attempt covering seventeen highincome countries. (2, 3)
3.3 Pharmacovigilance and the national drug
regulatory authority
Pharmacovigilance has become an essential
component of drug regulation. For the

forthcoming future of developing countries,
this is likely to take the traditional form of
spontaneous monitoring, even though it is a far
from perfect system. Many developing countries
lack the primary fundamental systems of
Pharmacovigilance. Further in some countries
even though these systems do exist, there
is lack of active support and participation
amongst health professionals, regulators and
administrators. In all countries the major
issue is proper interpretation of ADRs by
healthcare professionals. Hence post-marketing
surveillance serves a distinct function within
the national drug regulatory authority, separate
from the process of evaluation and approval of
new medicines. (2, 3)
(The importance of pharmacovigilance, Safety
monitoring of medicinal products, WHO 2002,
Chapter 4)
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